PALVELLA THERAPEUTICS, INC. Operating Income (Loss) in USD from Q2 2013 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Palvella Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2013 to Q3 2025.
  • Palvella Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2025 was -$10.2M, a 101% decline year-over-year.
  • Palvella Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2025 was -$31.7M, a 966% decline year-over-year.
  • Palvella Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$14.1M, a 18.8% decline from 2023.
  • Palvella Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$11.9M, a 72.7% increase from 2022.
  • Palvella Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$43.5M, a 16.1% increase from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)

PALVELLA THERAPEUTICS, INC. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$31.7M -$10.2M -$5.12M -101% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-12
Q2 2025 -$26.5M -$9.25M -$6.34M -218% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-14
Q1 2025 -$20.2M -$7.87M -$6.11M -347% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-15
Q4 2024 -$14.1M -$4.37M -$17.8M -133% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-31
Q3 2024 $3.66M -$5.06M +$6.75M +57.1% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-12
Q2 2024 -$3.09M -$2.91M -$4.97M -241% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-14
Q1 2024 $1.88M -$1.76M +$13.8M +88.7% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-15
Q4 2023 -$11.9M $13.4M +$24.9M Oct 1, 2023 Dec 31, 2023 10-K 2025-03-31
Q3 2023 -$36.8M -$11.8M +$361K +2.97% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 -$37.1M $2.06M +$14.4M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$51.5M -$15.5M -$8.05M -108% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 -$43.5M -$11.5M -$520K -4.73% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-29
Q3 2022 -$43M -$12.2M +$6.84M +36% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$49.8M -$12.3M +$4.43M +26.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$54.2M -$7.46M -$2.4M -47.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$51.8M -$11M +$1.41M +11.4% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 -$53.2M -$19M -$6.01M -46.3% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-04
Q2 2021 -$47.2M -$16.8M -$12.1M -260% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$35.1M -$5.06M -$1.2M -31.2% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-11
Q4 2020 -$33.9M -$12.4M -$11.1M -833% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-02
Q3 2020 -$22.8M -$13M -$10.1M -346% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-02
Q2 2020 -$12.8M -$4.66M +$7.58M +61.9% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 -$20.3M -$3.86M +$6.83M +63.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
Q4 2019 -$27.2M -$1.33M +$11.3M +89.5% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-31
Q3 2019 -$38.5M -$2.91M +$4.89M +62.7% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-04
Q2 2019 -$43.4M -$12.2M -$9.99M -445% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 -$33.4M -$10.7M -$2.55M -31.3% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 -$30.8M -$12.6M -$19.1M -295% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-13
Q3 2018 -$11.7M -$7.8M -$2.62M -50.5% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 -$9.08M -$2.24M +$5.65M +71.6% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-09
Q1 2018 -$14.7M -$8.14M -$130K -1.62% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-10
Q4 2017 -$14.6M $6.49M +$12.9M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-18
Q3 2017 -$27.5M -$5.18M +$994K +16.1% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-07
Q2 2017 -$28.5M -$7.89M -$2.1M -36.2% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
Q1 2017 -$26.4M -$8.01M -$3.63M -82.8% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-10
Q4 2016 -$22.8M -$6.4M -$3.84M -150% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-15
Q3 2016 -$18.9M -$6.18M -$2.3M -59.2% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-13
Q2 2016 -$16.6M -$5.8M -$2.26M -64% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-11
Q1 2016 -$14.4M -$4.38M -$679K -18.4% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-15
Q4 2015 -$13.7M -$2.57M -$649K -33.9% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-30
Q3 2015 -$13M -$3.88M -$2.04M -111% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-10
Q2 2015 -$11M -$3.53M -$765K -27.6% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-11
Q1 2015 -$10.2M -$3.7M -$3.03M -451% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-12
Q4 2014 -$7.2M -$1.92M -$1.91M Oct 1, 2014 Dec 31, 2014 10-K 2016-03-23
Q3 2014 -$5.28M -$1.84M -$1.84M Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-13
Q2 2014 -$3.45M -$2.77M -$2.77M Apr 4, 2014 Jun 30, 2014 10-Q 2015-08-13
Q1 2014 -$679K -$671K Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-14
Q4 2013 -$2.2K* Oct 1, 2013 Dec 31, 2013 10-Q 2014-05-14
Q3 2013 -$5.76K* Jul 1, 2013 Sep 30, 2013 10-Q 2014-12-12
Q2 2013 -$274* May 24, 2013 Jun 30, 2013 10-K 2014-09-12

PALVELLA THERAPEUTICS, INC. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$14.1M -$2.23M -18.8% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-31
2023 -$11.9M +$31.6M +72.7% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-31
2022 -$43.5M +$8.36M +16.1% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-29
2021 -$51.8M -$17.9M -52.8% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-31
2020 -$33.9M -$6.76M -24.9% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-02
2019 -$27.2M +$3.67M +11.9% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-31
2018 -$30.8M -$16.2M -111% Jan 1, 2018 Dec 31, 2018 10-K 2020-03-13
2017 -$14.6M +$8.17M +35.9% Jan 1, 2017 Dec 31, 2017 10-K 2019-03-18
2016 -$22.8M -$9.08M -66.4% Jan 1, 2016 Dec 31, 2016 10-K 2018-03-15
2015 -$13.7M -$6.48M -90.1% Jan 1, 2015 Dec 31, 2015 10-K 2017-03-30
2014 -$7.2M -$7.75M -1400% Jan 1, 2014 Dec 31, 2014 10-K 2016-03-23
2013 $554K Jan 1, 2013 Dec 31, 2013 10-K 2015-03-30
* An asterisk sign (*) next to the value indicates that the value is likely invalid.